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800become clinically apparent until
it has progressed to an advanced
stage, when sequelae such as
myocardial infarction, progressive
heart failure, or arrhythmic sudden
death ensue. Screening is therefore
required for its early detection.
Coronary intravascular ultra-
sonography (IVUS) is considered
the gold standard technique for
diagnosing CAV; however, its
broad clinical use in this context is
limited by cost and lack of wide-
spread expertise, and its evalua-
tion is limited to epicardial vessels
(5). Invasive coronary angiog-
raphy has a low sensitivity for
detecting CAV because of the
diffuse nature of the disease with
a lack of normal reference seg-
ments, and relatively late occur-
ring luminal narrowing (6).Furthermore, angiography is associated with signiﬁcant,
albeit uncommon, complications, and repeated studies are
costly and carry a considerable cumulative radiation burden.
However, despite these shortcomings, angiography has a
Class I recommendation for CAV screening, and annual or
biannual surveillance angiography is performed routinely in
most centers (7).
Noninvasive imaging approaches to the detection of CAV
offer a number of theoretical advantages; however, the
ﬁndings of the majority of studies assessing their diagnostic
performance have been unconvincing (8). Importantly, most
such studies have been limited by the use of coronary
angiography as the reference standard, with stenoses of 50%
or 70% as the signiﬁcance thresholds, despite adverse events
frequently occurring well before such advanced disease is
reached (9). Furthermore, none has included reference
assessment of the microvasculature.
Cardiovascular magnetic resonance (CMR) is a potentially
attractive screening modality for CAV due to its lack of
ionizing radiation and its multiparametric nature, namely, its
ability to assess multiple aspects of pathology in a single
examination (including ventricular function, myocardial
perfusion, and myocardial tissue characterization). Systematic
evaluation of multiparametric CMR for the diagnosis of CAV
has not been reported to date. The aim of this study was to
evaluate the diagnostic performance of multiparametric CMR
in CAV, and to compare it with that of invasive coronary
angiography, using contemporary invasive epicardial artery and
microvascular assessment techniques as reference standards.Figure 1 Recruitment Data
The number of patients approached, excluded, and recruited.Methods
Patients and study design. All heart transplant recipients
referred for CAV surveillance coronary angiography atUniversity Hospital of South Manchester NHS Trust,
United Kingdom (1 of 6 UK adult heart transplant centers),
between November 1, 2010, and November 1, 2012, were
prospectively screened for study eligibility (Fig. 1). Patients
were excluded if they had a contraindication to CMR or
adenosine infusion, an estimated glomerular ﬁltration rate of
35 ml/min/1.73 m2 or less, or current conﬁrmed or sus-
pected acute allograft rejection.
In addition, 10 age- and sex-matched healthy volunteers
were recruited. The volunteers were completely asymptom-
atic with no known risk factors or history of cardiac disease,
normal physical examination, and normal electrocardiogram
(i.e., they were not patients who had been referred for CMR
that was subsequently found to be normal).
Patients underwent coronary angiography, followed
immediately by invasive coronary physiological measure-
ments and coronary intravascular ultrasonography (IVUS) as
described in the following text. Within 1 month of the
invasive investigations, patients underwent multiparametric
CMR assessment. The order of the invasive assessment and
CMR was determined randomly, and no patient had an
interim cardiovascular event. Healthy volunteers underwent
CMR only. An ethics committee of the UK National
Research Ethics Service approved the study, and written
informed consent was obtained from all participants. The
work was conducted according to the Helsinki Declaration.
Invasive investigations. CORONARY ANGIOGRAPHY. Coro-
nary angiography was performed according to the standard
Judkin technique with a 6F system. Multiple projections of
the coronary arteries were acquired, including at least 2
orthogonal views of the proximal, mid, and distal left
anterior descending (LAD) artery.
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801PHYSIOLOGICAL MEASUREMENTS. After acquiring the
angiographic images, 70 IU/kg heparin was administered
intravenously, and a 6-F guiding catheter was used to
engage the left coronary artery. Intracoronary nitroglycerin
(200 mg) was given. A 0.014-inch coronary pressure wire
(Radi Medical Systems, St. Jude Medical, St. Paul, Min-
nesota) was calibrated, equalized, and advanced to the distal
portion of the LAD. Maximal hyperemia was induced by
administration of intravenous adenosine (140 mg/kg/min)
through a 18G cannula in a large peripheral vein for 3 min
before and during data acquisition. Hyperemic mean
transit time was determined by averaging the transit times
of 3  3 ml boluses of room temperature saline. Mean
aortic and distal coronary pressures were recorded. Metic-
ulous attention was paid to guide catheter engagement.
Fractional ﬂow reserve (FFR) was calculated by dividing
the mean distal coronary pressure by the mean proximal
coronary pressure during hyperemia. Index of microcircu-
latory resistance (IMR) was calculated by multiplying the
distal coronary pressure by the hyperemic mean transit
time, measured simultaneously (10).
INTRAVASCULAR ULTRASONOGRAPHY. After the physiological
measurements, a 40 MHz IVUS catheter (Atlantis SR Pro,
Boston Scientiﬁc, Natick, Massachusetts) was advanced over
the wire, so that the transducer was positioned in the distal
artery, as close as possible to the pressure transducer
mounted on the pressure wire. Automated pullback at a
constant rate of 0.5 mm/s was performed along the length of
the vessel.
Cardiovascular magnetic resonance. The CMR was per-
formed using a 1.5-T scanner (Avanto, Siemens Medical
Imaging, Erlangen, Germany) equipped with a 32-element
phased-array coil.
GLOBAL AND REGIONAL LEFT VENTRICULAR FUNCTION.
Steady-state free precession cine images were acquired in
standard long-axis views and in a stack of short-axis slices
covering the left ventricle (LV). Short-axis tagged images
were acquired at basal, mid, and apical ventricular levels
using a segmented k-space fast gradient echo sequence with
spatial modulation of magnetization in orthogonal planes.
PERFUSION. Using a saturation recovery gradient echo
sequence, basal, mid, and apical short-axis images were
acquired every heartbeat during pharmacological vasodilation
(“stress”) and at rest. For stress imaging, intravenous adeno-
sine (140 mg/kg/min) was administered through a 18G
cannula in a large peripheral vein for 3 min before, and
during, data acquisition. A 0.05 mmol/kg bolus of
gadolinium-based contrast agent (gadopentetate dimeglu-
mine [Gd-DTPA]; Magnevist, Bayer HealthCare, Wup-
pertal, Germany) was administered intravenously at 5 ml/s
followed by a 30-ml saline ﬂush. Rest imaging was performed
10 min after stress imaging with a further 0.05 mmol/kg of
contrast agent. After rest perfusion image acquisition, a
further 0.1 mmol/kg of contrast agent was administered to
bring the total dose to 0.2 mmol/kg.TISSUE CHARACTERIZATION. A single-shot modiﬁed Look
Locker inversion recovery sequence was acquired in short-
axis view at midventricular level before the contrast agent
was administered, and 15 min after the ﬁnal dose of the
contrast agent (11). Blood samples were taken at the time of
CMR to measure hematocrit. Standard late gadolinium
enhancement imaging was performed at least 10 min after
the ﬁnal dose of the contrast agent using spoiled gradient
echo segmented inversion recovery and phase-sensitive
inversion recovery segmented gradient echo sequences.
Image analysis. QUANTITATIVE CORONARY ANGIOGRAPHY.
Angiographic images were analyzed using quantitative cor-
onary angiography, performed on the proximal, mid, and
distal LAD with guiding catheter calibration (QAngio XA,
Medis Medical Imaging Systems, Leiden, the Netherlands).
Reference and minimal lumen diameters for the 3 sites were
measured, and the greatest percent diameter stenosis was
recorded.
INTRAVASCULAR ULTRASOUND. Quantitative analysis was
performed using QIVUS (Medis Medical Imaging Sys-
tems), according to the method described by Fearon et al.
(12). The external elastic lamina and luminal border were
traced on images acquired every 0.1 mm. “Plaque area” (also
known as intima-media area) was calculated as vessel area
minus luminal area. By means of Simpson’s method, vessel
volume, luminal volume, and hence, plaque volume were
calculated as the sum of the respective areas multiplied by
the “segment” length of 0.1 mm. Subsequently the plaque
volume index, deﬁned as plaque volume expressed as a
percentage of vessel volume, was calculated to normalize for
vessel size and length of IVUS pullback.
Cardiovascular magnetic resonance. FUNCTIONAL ANALYSIS.
The LV mass, end-diastolic volume, end-systolic volume,
and ejection fraction (EF) were quantiﬁed from steady-state
free precession images using CMRtools (Cardiovascular
Imaging Solutions, London, United Kingdom) (13). Peak
systolic circumferential strain (εcc) and strain rate (systolic
and early diastolic) were measured from midventricular
short-axis tagged images using SinMod (inTag software,
version 5.0, CREATIS Laboratory, Lyon, France; and
Maastricht University, the Netherlands) (14). Basal and
apical short-axis rotation, calculated from basal and apical
tagged images using the same software, and epicardial areas,
measured on corresponding steady-state free precession
images, were incorporated into a custom-written algorithm
(Microsoft Excel using Visual Basic). After expression of
time coordinates as a percentage of systolic duration (time
between peak electrocardiogram R-wave and aortic valve
closure) and cubic spline interpolation, twist was calculated
by subtracting basal rotation from apical rotation at each
time point. Normalized twist was calculated as the twist
angle divided by distance between basal and apical slice
positions. Torsion (represented by an approximation of the
circumferential-longitudinal shear angle) was calculated by
multiplying normalized twist by the mean of the basal and
apical epicardial radii at each time point.
Table 1 Subject Characteristics
Transplant
Patients
(n ¼ 48)
Healthy
Volunteers
(n ¼ 10) p Value
Male 41 (85%) 8 (80%) 0.674
Age, yrs 51  14 48  8 0.560
Male 52  13 48  8 0.377
Female 46  19 51  10 0.742
Nonwhite 5 (10%) 1 (10%) 0.969
Weight, kg 86.0  16.3 82.1  12.5 0.471
Height, m 1.71  0.06 1.77  0.10 0.015
BSA, m2 1.98  0.19 1.99  0.18 0.841
BMI, kg/m2 29.4  4.9 26.3  4.0 0.066
eGFR, ml/min/m2 58  16 87  13 <0.001
HR, beats/min 80  12 61  7 <0.001
Systolic BP, mm Hg 124  18 114  9 0.079
Diastolic BP, mm Hg 78  12 69  6 0.030
RPP 9.83  1.75 6.92  1.22 <0.001
Values are n (%) or mean  SD.
BMI ¼ body mass index; BP ¼ blood pressure; BSA ¼ body surface area; eGFR ¼ estimated
glomerular ﬁltration rate; HR ¼ heart rate; RPP ¼ rate pressure product (systolic blood pressure 
heart rate  0.001).
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802PERFUSION QUANTIFICATION. Endocardial and epicardial
contours were drawn on the perfusion images using Osirix
Imaging Software, version 4.0 (Pixmeo, Geneva, Switzerland).
An additional region of interest (ROI) was drawn in the
blood pool on the basal images, avoiding papillary muscles
and trabeculae. The ROIs were manually translated on each
perfusion image of the same slice to compensate for rigid-
body translational motion. Perfusion quantiﬁcation was
performed in MatLab, version R2009a (MathWorks,
Natick, Massachusetts) using algorithms written in house.
Signal intensity curves were extracted from the average
signal in the blood pool, to provide an arterial input func-
tion, and on a voxel-wise basis from the myocardial ROI.
Signal intensity was converted to contrast agent concentra-
tion (15). Data for quantitative perfusion analysis were
restricted to the ﬁrst pass of the contrast agent through the
heart, which was automatically detected from the blood
pool signal curve. Perfusion values were obtained on a voxel-
wise basis using generalized Tikhonov deconvolution with a
b-spline representation of the impulse response function
(16). Myocardial perfusion reserve (MPR) was calculated by
dividing median hyperemic myocardial blood ﬂow (MBF)
by median resting MBF.
TISSUE CHARACTERIZATION. The LGE images were re-
ported visually by 2 experienced operators, and the presence
or absence of LGE, and its distribution pattern, were
recorded. Myocardial T1 relaxation time was measured
by drawing endocardial and epicardial contours on the
modiﬁed Look Locker inversion recovery images using
Osirix Imaging Software, version 4.0 (Pixmeo). In keeping
with Wong et al. (17), myocardium in the vicinity of
infarcted myocardium was excluded, but foci of LGE in
myocardium free from infarction were not excluded. An
additional ROI was drawn in the blood pool for measure-
ment of blood T1. The ROIs were manually translated on
each effective inversion time (TIeff) image to compensate for
rigid-body translational motion. To obtain voxel-wise T1
relaxation maps, a 3-parameter ﬁt to the signal intensity,
S as a function of TIeff was performed according to
S(TIeff) ¼ A  Be(-TIeff/T1*), and T1 was calculated as
T1 ¼ T1*((B/A)  1). Fitting was carried out using MatLab,
version R2009a (MathWorks). After applying a heart-rate
correction algorithm, mean midventricular pixel T1 relaxa-
tion times before and after contrast were then used to
calculate myocardial extracellular volume according to
the following formula: extracellular volume fraction
(ECV) ¼ l  (1 hematocrit), where the partition coefﬁ-
cient, l ¼ DR1(myocardium) / DR1(blood). The DR1
is proportional to contrast agent concentration: DR1 ¼
R1(post-contrast)  R1(pre-contrast).
Statistical analysis. All data were analyzed in a blinded
fashion, with independent analysis of CMR and invasive
data. The IVUS plaque volume index and IMR were used as
the reference standards for epicardial and microvascular
disease, respectively (see the Discussion section). Statistical
analysis was performed using SPSS, version 19 (IBM,Armonk, New York), and STATA, version 11.0 (Stata-
Corp, College Station, Texas). Continuous variables are
expressed as mean  SD unless stated. An independent-
samples t test (or Mann-Whitney U test where appro-
priate) was used to compare data from transplant patients
and healthy volunteers. Linear regression was used to
investigate possible associations between continuous invasive
and CMR data, and stepwise selection methods were used to
determine the most important associations. Separate step-
wise analyses were performed for the angiographic and
CMR data. Because of the relatively small size of the study,
the number of univariable associations entered into the
multivariable model was limited to 5, and overlapping var-
iables were avoided. Receiver-operating characteristic
(ROC) curve analyses were used to determine optimal cut-
off points for CMR MPR and coronary angiographic ste-
nosis, respectively, for detecting CAV (epicardial and
microvascular disease), and estimates of sensitivity and
speciﬁcity were derived. Given the absence of well-deﬁned
severity thresholds, the 75th centile (“severe disease”) and
median values (“moderate disease”) for both plaque volume
index and IMR were used to deﬁne the presence of
epicardial and microvascular disease, respectively. The
diagnostic performance of CMR MPR and coronary angi-
ography were compared using a chi-square comparison of
the trapezoidal area under the respective ROC curves.Results
Study population. Forty-eight patients were recruited
(Fig. 1). In 2 patients the LAD was occluded, meaning that
IVUS and invasive coronary physiological assessment were
not possible (for the purpose of the subsequent ROC curve
analyses, both were considered to have severe epicardial
Table 3
Associations With Intravascular Ultrasound
Plaque Volume Index
Univariable Associations b p Value
Patient characteristics
Age 0.15 0.325
Time since transplantation 0.49 0.001
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803disease). Three patients underwent CMR without gadolin-
ium contrast (estimated glomerular ﬁltration rate deteriorated
to <35 ml/min/1.73 m2 between the invasive studies and
CMR in 2 patients, and 1 patient terminated the scan
early because of claustrophobia). There were no complications.
Demographic data are presented in Table 1 and Online
Table 1. Median time from transplantation to enrollment
was 7.1 years (interquartile range: 4.6 to 10.3 years).
Invasive investigations. Mean plaque volume index was
22.4  9.8% and mean maximal intima-media thickness was
1.21  0.57 mm. Mean FFR was 0.90  0.06. An
FFR <0.80 was observed in 1 patient (2%). Mean IMR was
23.7  12.5. There was a signiﬁcant correlation between
plaque volume index and FFR (r ¼ 0.46, p ¼ 0.001), but
there was no correlation between plaque volume index and
IMR (r ¼ 0.24, p ¼ 0.103). The FFR was seen to improve
as IMR deteriorated (r ¼ 0.32, p ¼ 0.028).
Mean maximum angiographic stenosis was 23.9  16.0%.
Maximum angiographic stenosis showed a signiﬁcant cor-
relation with plaque volume index (r ¼ 0.33, p ¼ 0.024) and
FFR (r ¼ 0.38, p ¼ 0.010). There was no correlation
between maximum angiographic stenosis and IMR
(r ¼ 0.16, p ¼ 0.281).
Cardiovascular magnetic resonance. The CMR data are
presented in Table 2 and Online Table 2. In keeping with the
signiﬁcantly higher resting rate pressure product seen in
transplant patients (Table 1), resting MBF was signiﬁcantly
higher in transplant patients than in healthy volunteers.
Stress MBF was signiﬁcantly lower in transplant recipients
compared with healthy volunteers, as was MPR. Signiﬁcant
differences were also seen between transplant patients and
healthy volunteers in indexed LV end-diastolic volume, εcc,Table 2
Comparison of Cardiovascular Magnetic Resonance
Findings in Transplant Patients and
Healthy Volunteers
Transplant
Patients
(n ¼ 48)
Healthy
Volunteers
(n ¼ 10) p Value
LVEDVI, ml/m2 74.5  15.1 86.6  7.7 0.018
LVESVI, ml/m2 28.0  8.8 28.2  4.4 0.951
LVstrokevolume index,ml/m2 46.5  9.5 58.4  6.5 <0.001
LVEF, % 62.9  7.6 67.5  4.3 0.069
LVMI, g/m2 50.0  11.3 47.8  7.3 0.544
εcc, % 14.48  3.33 20.4  1.48 <0.001
Twist, degree 9.08  3.38 12.42  3.45 0.007
Resting MBF, ml/min/g 0.86  0.10 0.74  0.09 0.001
Stress MBF, ml/min/g 1.50  0.40 1.77  0.24 0.043
MPR 1.74  0.45 2.42  0.36 <0.001
LGE (n ¼ 45) 22 (49%) 0
Infarct LGE 4 (9%) 0
Atypical LGE 22 (49%) 0
Myocardial ECV, % 29.0  4.3 25.3  1.8 0.011
Values are mean  SD. The sufﬁx “I” indicates indexed to body surface area. Additional data can be
found in the Online Table 2.
ECV ¼ extracellular volume; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; εcc ¼ peak
systolic circumferential strain; ESV ¼ end-systolic volume; LGE ¼ late gadolinium enhancement;
LV ¼ left ventricle; MBF ¼myocardial blood ﬂow; MPR ¼myocardial perfusion reserve; SV ¼ stroke
volume.and twist, but not in normalized twist, torsion, or time to
peak torsion (i.e., time to onset of untwisting). Atypical LGE
was seen in almost half of transplant recipients, and 4 of
those (9% of the study population) also had infarct-typical
LGE. Inferior right ventricular septal insertion point
enhancement was the most common type of atypical LGE
(16 patients; 36%), but midwall (5 patients; 11%), “punched-
out” (4 patients; 9%) and epicardial (2 patients; 4%) patterns
were also observed. Pericardial LGE was observed in 3 pa-
tients (7%). Myocardial ECV was signiﬁcantly higher in
transplant patients compared with healthy volunteers.
Associations with plaque volume index. On univariable
analysis, maximum angiographic stenosis showed a signiﬁ-
cant association with plaque volume index; however, after
correcting for time since transplantation, this relationship
was no longer signiﬁcant (p ¼ 0.295) (Table 3, Online
Table 3). Early diastolic strain rate, stress MBF, MPR and
infarct LGE were signiﬁcantly associated with plaque volume
index on univariable analyses, but only MPR and early dia-
stolic strain rate remained independently associated with
plaque volume index on multivariable analysis (Fig. 2A).
Associations with index of microcirculatory resistance.
Maximum angiographic stenosis was not signiﬁcantly asso-
ciated with IMR on univariable analysis (Table 4). PatientDonor age 0.29 0.058
Angiography
Maximum angiographic stenosis 0.33 0.024
CMR
LVEF 0.17 0.257
LVMI 0.18 0.229
εcc 0.17 0.263
Early diastolic SR 0.38 0.014
Resting MBF 0.10 0.515
Stress MBF 0.51 0.001
MPR 0.55 <0.001
LGE 0.22 0.151
Infarct LGE 0.35 0.022
Atypical LGE 0.22 0.151
ECV 0.06 0.740
Multivariable Stepwise Regression b p Value R2
A. Including patient characteristics
and angiographic data
Time since transplantation 0.49 0.001 0.24
B. Including patient characteristics
and CMR data
Time since transplantation 0.47 <0.001 0.58
Early diastolic SR, 1/s 0.24 0.049
MPR 0.57 <0.001
Selected patient characteristics are shown. Additional data can be found in the Online Table 3.
Separate multivariable analyses were performed for (A) angiographic and (B) CMR data.
SR ¼ strain rate; other abbreviations as in Table 2.
Table 4
Associations With Index of
Microcirculatory Resistance
Univariable Associations b p Value
Patient characteristics
Age 0.26 0.085
Time since transplantation 0.18 0.224
Donor age 0.39 0.007
Donor hypertension 0.35 0.016
Recipient:donor BMI ratio 0.31 0.043
Angiography
Maximum angiographic stenosis 0.16 0.281
CMR
LVEF 0.36 0.015
LVMI 0.16 0.288
εcc 0.46 0.002
Resting MBF 0.05 0.762
Stress MBF 0.54 <0.001
MPR 0.55 <0.001
LGE 0.12 0.463
Infarct LGE 0.16 0.299
Atypical LGE 0.12 0.463
ECV 0.10 0.588
Multivariable Stepwise Regression b p Value R2
Donor hypertension 0.29 0.012 0.58
EF 0.26 0.024
MPR 0.60 <0.001
Selected patient characteristics are shown. Additional data can be found in the Online Table 4.
Abbreviations as in Table 2.
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804characteristics including donor age, the presence of hyper-
tension in the donor, and recipient:donor body mass index
ratio showed signiﬁcant associations with IMR on uni-
variable analyses, as did CMR parameters such as EF, εcc,
stress MBF, and MPR. On multivariable analysis only
donor hypertension, EF, and MPR remained independently
associated with IMR (Fig. 2B).
Diagnostic performance of cardiovascular magnetic
resonance and angiography. In light of the multivariable
regression results, MPR was the only CMR parameter used
for ROC curve analysis. The diagnostic performance of
angiography and CMR MPR are displayed in Table 5.
When epicardial and microvascular disease were considered
together, as in vivo, CMR MPR outperformed angiography
(chi-square ¼ 6.6, p ¼ 0.01 for detecting moderate epicar-
dial or microvascular disease; chi-square ¼ 3.7, p ¼ 0.05 for
detecting severe epicardial or microvascular disease) (Fig. 3).
Associations with myocardial perfusion reserve. There
was no association between MPR and maximum angio-
graphic stenosis (b ¼ 0.11, p ¼ 0.469) or between MPR
and FFR (b ¼ 0.13, p ¼ 0.415). On univariable analysis,
donor age (b ¼ 0.32, p ¼ 0.038), LV mass index
(b ¼ 0.34, p ¼ 0.021), εcc (b ¼ 0.32, p ¼ 0.049),
infarct LGE (b ¼ 0.29, p ¼ 0.051), and ECV
(b ¼ 0.34, p ¼ 0.045) were associated with MPR; but on
multivariable stepwise regression only LV mass index
(b ¼ 0.39, p ¼ 0.015) and infarct LGE (b ¼ 0.36,
p ¼ 0.025) remained independently associated with MPR.Discussion
This study provides comprehensive assessment of cardiac
structure and function in the medium to long term after
heart transplantation. The MPR, on the basis of measure-
ment of absolute stress and rest MBF using CMR, was theFigure 2 CMR MPR Plotted Against IVUS Plaque Volume Index and
Cardiovascular magnetic resonance (CMR) myocardial perfusion reserve (MPR) plotted ag
plaque volume index; and (B) microvascular disease, assessed using index of microcircuonly independent predictor of both epicardial and micro-
vascular disease, and its diagnostic performance was signif-
icantly greater than that of invasive coronary angiography,
the current clinical standard.
Invasive benchmarks. CAV is an exempliﬁer of a disease
that affects both the epicardial and microvascular coronaryIMR
ainst (A) epicardial disease, assessed using intravascular ultrasound (IVUS)
latory resistance (IMR).
Table 5
Diagnostic Performance of Coronary Angiography and Cardiovascular Magnetic
Resonance Myocardial Perfusion Reserve
AUC Cut-Off Sensitivity Speciﬁcity
Diagnostic performance of angiographic
stenosis for detecting
Severe epicardial disease 0.70 (0.52–0.87) 21.09 0.69 0.63
Moderate epicardial disease 0.56 (0.39–0.72) 19.77 0.60 0.57
Severe microvascular disease 0.49 (0.30–0.67) 19.49 0.55 0.49
Moderate microvascular disease 0.44 (0.27–0.61) 19.40 0.57 0.48
Severe epicardial or microvascular disease 0.67 (0.52–0.82) 19.49 0.70 0.57
Moderate epicardial or microvascular disease 0.59 (0.42–0.77) 19.09 0.65 0.57
Diagnostic performance of CMR MPR
for detecting
Severe epicardial disease 0.79 (0.66–0.92) 1.58 0.77 0.78
Moderate epicardial disease 0.76 (0.60–0.91) 1.83 0.84 0.70
Severe microvascular disease 0.85 (0.70–0.99) 1.45 0.80 0.85
Moderate microvascular disease 0.71 (0.55–0.87) 1.74 0.71 0.64
Severe epicardial or microvascular disease 0.88 (0.78–0.98) 1.65 0.79 0.85
Moderate epicardial or microvascular disease 0.89 (0.79–1.0) 1.94 0.88 0.85
Receiver-operating characteristic curve analysis. Severe epicardial disease refers to >75th centile for intravascular ultrasound plaque volume index;
moderate refers to above the median value. Severe microvascular disease refers to >75th centile for index of microcirculatory resistance; moderate
refers to above the median value. Cut-off values for cardiovascular magnetic resonance (CMR) myocardial perfusion reserve (MPR) refer to MPR values
less than or equal to this value. Cut-off values for maximum angiographic stenosis (%) refer to stenotic values greater than or equal to this value.
AUC ¼ area under the curve.
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805compartments. In keeping with histological work and other
invasive coronary physiology studies, the current study serves
to conﬁrm that CAV affects the epicardial arteries and the
microvasculature independently (2,3,18,19). Comprehensive
assessment of CAV, both in terms of evaluating disease
severity and evaluating the performance of new diagnostic
approaches, therefore requires assessment of both compart-
ments. The current study is the ﬁrst to evaluate a diagnostic
approach to CAV with epicardial and microvascular
benchmarks.Figure 3 Diagnostic Performance of CMR MPR and Angiography for
Diagnostic performance of cardiovascular magnetic resonance (CMR) (blue lines) myoca
moderate cardiac allograft vasculopathy, deﬁned as more than median epicardial or micr
>75th centile epicardial or microvascular disease.In the present study IVUS, rather than FFR, was used as
the epicardial reference standard. IVUS is generally regarded
as the gold standard technique for epicardial artery assess-
ment in CAV and is considerably more established, and a
number of studies have demonstrated that IVUS-derived
vessel wall parameters, irrespective of hemodynamic signif-
icance, predict outcome in transplant recipients (20–24).
In addition, because of the complex interplay between
epicardial and microvascular disease, FFR may not provide
a good indication of epicardial disease in CAV. HirohataDetecting CAV
rdial perfusion reserve (MPR) and angiography (Angio) (red lines) for detecting (A)
ovascular disease; and (B) severe cardiac allograft vasculopathy, deﬁned as
Miller et al. JACC Vol. 63, No. 8, 2014
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806et al. (25) found that in patients >2 years post-transplant,
for a given plaque burden, FFR varied signiﬁcantly accord-
ing to IMR; with FFR seen to improve (i.e., increase/
become closer to 1.0) as IMR deteriorated (increased).
These ﬁndings are directly in keeping with the ﬁndings of
the current study, where FFR and IMR were shown to have
a signiﬁcant positive correlation. These observations reﬂect
that in the setting of microvascular dysfunction, maximal
achievable coronary ﬂow is diminished, and thus the impact
of an epicardial stenosis is lessened.
Such observations are not unique to CAV. For example,
in the case of a given epicardial stenosis, FFR will be lower
when the artery subtends viable myocardium (i.e., with
minimal microvascular resistance, hence a large “pressure
drop” down the artery) compared with if the artery were to
supply infarcted myocardium (i.e., substantial microvascular
resistance, hence a smaller pressure drop). Nevertheless,
given the prevalence and importance of microvascular dis-
ease in CAV, these ﬁndings led Hirohata et al. (25) to
conclude that “FFR may not provide a good representation
of epicardial plaque burden late (i.e., more than 2 years) after
heart transplantation.” Indeed, over a number of studies, the
correlation between FFR and IVUS parameters has varied
considerably, from no correlation to a correlation coefﬁcient
of 0.58 (19,23).
In keeping with most other contemporary CAV studies,
plaque volume index, rather than other IVUS parameters
such as intima-media thickness, was used as it better reﬂects
disease burden (12,19). In the absence of established disease
severity cut-offs, 75th centile and median values were
pragmatically chosen for ROC curve analysis. The IMR was
used instead of invasive coronary ﬂow reserve to assess the
microvasculature because, unlike coronary ﬂow reserve, IMR
is speciﬁc for the microcirculation (i.e., independent of
epicardial artery function) and largely independent of he-
modynamic variations, and is more reproducible (10,26,27).
Median and 75th centile IMR values were used for ROC
curve analysis in keeping with other studies (28,29).
Epicardial and microvascular disease severity in the current
study was almost identical to that in the previous largest
studies, and hence the disease severity thresholds used here
appear reasonable (4,12,19,25).
Myocardial blood ﬂow. The myocardial perfusion ﬁndings
with regard to epicardial artery disease in the current study
are in keeping with the results of 2 smaller studies that
assessed MBF in CAV using 13N-ammonia positron
emission tomography. Kofoed et al. (30) and Wu et al. (31)
found MPR and hyperemic MBF to be inversely related to
IVUS parameters of CAV severity, with very similar uni-
variable correlations to those found here (MPR: correlation
coefﬁcients up to 0.61 and 0.40, respectively, in the
studies by Kofoed et al. and Wu et al. compared to a b value
of 0.55 in the current study; hyperemic MBF: 0.49
and 0.46, respectively, compared to 0.51 in the current
study). Also in keeping with the current study, in both
positron emission tomography studies, resting MBF washigher in transplant patients than in control subjects, at least
in part secondary to the higher resting heart rate seen in
transplant recipients due to allograft vagal denervation, and
was unrelated to the severity of epicardial artery disease.
A number of studies in other cardiovascular diseases have
considered microvascular dysfunction to be present when
MPR, or hyperemic MBF, are reduced in the presence of
normal epicardial arteries (usually assessed with angiog-
raphy) (32,33). Other studies have demonstrated a correla-
tion between MPR and invasive coronary ﬂow reserve
(measured using intracoronary Doppler) in patients without
signiﬁcant epicardial coronary stenoses (34,35). To our
knowledge, the current study is the ﬁrst in any cardiac
pathology to demonstrate that MPR, and hyperemic MBF,
are independent predictors of microvascular function, when
microvascular function itself is independently measured.
Highlighting the importance of microvascular disease in
CAV, MPR was governed by epicardial and microvascular
disease to a similar degree.
The inverse association between MPR and LV mass in-
dex seen here has been described in other conditions where
microvascular dysfunction is prominent (36–38), but this is
the ﬁrst time it has been demonstrated in transplanted
hearts. There was also an association between the presence
of infarct-typical LGE and reduced MPR; however,
although myocardial extracellular volume was inversely
associated with MPR on univariable analysis, the relation-
ship did not remain signiﬁcant on multivariable analysis.
The discordance seen here between MPR and FFR is in
keeping with that reported in other conditions and, as
described by Johnson et al. (39), is likely to reﬂect the nature
of the coronary pathophysiology involved.
Myocardial tissue characterization. Infarct prevalence in
the current study (9%) was in keeping with the study by
Butler et al. (11%) (40), although lower than in the study by
Steen et al. (37%) (41); however, the cohort studied by Steen
et al. represented advanced epicardial disease (including 19%
with focal angiographic stenoses of 75%). The prevalence
of infarct-atypical LGE in the current study (49%) was very
similar to that found by Butler et al. (40%) (40) and by Steen
et al. (51%) (41), and as in these other studies, was unrelated
to epicardial disease. In addition to these other studies,
which did not have a microvascular reference, the current
study showed that infarct-atypical LGE was unrelated to
microvascular disease.
Myocardial mechanics. In keeping with the ﬁndings of
Weis et al. (42), who used CFR to assess microvascular
dysfunction in patients with angiographically normal
epicardial arteries, microvascular function was indepen-
dently associated with LV function, which may reﬂect
chronic subendocardial ischemia leading to impaired LV
function. Early diastolic strain rate was independently
associated with epicardial disease, which is in keeping with
the study by Korosoglou et al. (43), but in general,
myocardial deformation parameters were not discriminatory
for CAV.
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807Why screen at all? It has been suggested that routine CAV
screening should not be performed at all given the lack of
evidence-based treatment options for improving symptoms
or prognosis in established disease, other than retrans-
plantation, which is possible in only a minority (44).
Certainly signiﬁcant luminal narrowing on angiography
represents advanced vascular disease that is unlikely to be
modiﬁable, and adverse events frequently occur well before
this degree of disease is reached (9). This study demonstrates
that CAV can potentially be detected noninvasively at a
much earlier stage using CMR-based MBF assessment,
which may allow earlier intensiﬁcation of preventative
therapy and may help pave the way for the development of
disease-modifying therapies. However, although the CMR
perfusion sequence used in the current study is in routine
clinical use, and thus could be readily applied, CMR MBF
quantiﬁcation is technically challenging, and although
considerable effort is being put into developing commercially
available quantiﬁcation software, at present it remains a
research tool. Furthermore, it should be noted that 30% of
patients screened had contraindications to CMR scanning
or gadolinium contrast agent, and, therefore, such an
approach would not be appropriate for all patients.
Study limitations. In keeping with the majority of studies
involving transplant recipients, the current study is a rela-
tively small, single–center study. The results require conﬁr-
mation in larger, multicenter studies. The IVUS and
invasive physiological assessments were performed on the
LAD only; however, that also is in keeping with most other
transplant studies (12). The IMR measurements were made
without taking collateral ﬂow into account (requiring balloon
occlusion of the vessel); however, that is in keeping with all
other studies using IMR in transplant recipients as collat-
eralization is not a feature of CAV (12,19). Finally, this is a
cross-sectional study and, therefore, the effect of disease
progression on CMR MPR, and the prognostic value of
CMR MPR, have not been assessed.Conclusions
In this comprehensive assessment of cardiac structure and
function in the medium to long term after transplantation,
CMR-based MPR was independently predictive of both
epicardial and microvascular components of CAV.
Furthermore, the diagnostic performance of CMR MPR
was signiﬁcantly higher than that of coronary angiography,
the current clinical screening technique.Acknowledgments
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